Insights On Upstream Manufacturing

1. Upstream Decisions Influence Downstream Challenges 7/1/2026

   In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), answer the question, “What should developers be thinking about upstream to avoid downstream complications?” Klyushnichenko believes process-wide considerations like this begin earlier than cell line development at the product’s molecular construct itself.

2. Productivity Gains Upstream Apply Pressure Downstream 7/1/2026

   In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), reflect on the progress that’s been made in terms of productivity gains and the “ceiling” that mAbs face, and how these upstream gains stress downstream operations. They also discuss how molecular complexity relates to challenges in purification.

3. Continuous Manufacturing As A Powerful Productivity Lever 7/1/2026

   In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), discuss the potential of perfusion and continuous manufacturing to improve productivity through smaller facility footprints and greater output over time. They also examine the challenges associated with these approaches, including cell-line stability, process monitoring, and the cost of operational mistakes.

4. Next-Generation Molecules Challenge Notions Of Yield And Performance 7/1/2026

   In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), discuss how the process-related associated with next-generation molecules like bispecifics and trispecifics complicate downstream purification efforts impurities (e.g., chain mispairings). They agree that mitigating these impurities is a developmental challenge both upstream and downstream.

5. Understanding Fixed Variables And Working Within Their Constraints 7/1/2026

   Some things are intrinsic, unchanging realities of a process — molecular complexity, product developability, and facility fit, to name a few. In this segment from the Bioprocess Online Live event, “The Levers And Tradeoffs That Drive Process Productivity,” panelists David Scherr, Ph.D. (AstraZeneca) and Vadim Klyushnichenko, Ph.D. (Calibr-Skaggs), discuss these “non-pullable levers” of process development and advise teams on how to work within their boundaries.

6. Breaking the Titer Ceiling: Smarter Media Design for Higher Productivity 6/30/2026

   A bottom-up, data-driven media design approach shows how targeted nutrient optimization overcomes metabolic limits to boost culture performance and titer while maintaining product quality and process consistency.

7. Is It Better To Scale Up Or Scale Out Your Cell Culture Platform? 6/29/2026

   Take a look at how adherent cell culture expansion affects space, labor, costs, contamination risk, and sustainability, helping teams weigh when a larger-footprint approach stops making sense.

8. Engineering The Future Of Antibody-Drug Conjugates 6/26/2026

   As ADCs expand into broader use, upstream process design is becoming a competitive advantage. Discover how smarter media strategies and data-driven decision-making are helping teams reduce risk.

9. Exploring The Future Of Cell Expansion In Cell Therapy Manufacturing 6/26/2026

   As cell therapy scales, success depends on more than clinical promise. Smarter expansion strategies, automation, and flexible manufacturing platforms are becoming critical for improving consistency.

10. Catalent Capabilities Update June 2026: Cell Line Development 6/24/2026

    Discover how an integrated approach to transient expression, cell line development, and manufacturing can accelerate biologics development from gene to IND.